FDA approves use of combo for hepatitis C in children

12/14/2008 | Winston-Salem Journal (N.C.)

Schering-Plough obtained FDA clearance to market a regimen that combines Rebetol -- an antiviral drug -- with Pegintron -- a bioengineered version of an immune-system protein called interferon -- to treat hepatitis C in children ages 3 to 17. The two-drug therapy offers extended effectiveness with the aid of pegylation, a technology used in Pegintron that allows it to remain in the blood longer.

View Full Article in:

Winston-Salem Journal (N.C.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN